Uterine Neoplasms

• 

  Subject Areas on Research

  • "Tips" on acute arthritis and clubbing. 
  • 5-day methotrexate for women with metastatic gestational trophoblastic disease. 
  • A Comparative Analysis of Health-Related Quality of Life 1 Year Following Myomectomy or Uterine Artery Embolization: Findings from the COMPARE-UF Registry. 
  • A Phase I Clinical Trial to Assess Safety and Tolerability of Injectable Collagenase in Women with Symptomatic Uterine Fibroids. 
  • A Rapidly Enlarging Müllerian-Derived Hepatic Adenomyoma Clinically Mimicking Hepatic Adenoma in a Pregnant Woman. 
  • A flexible parametric model for combining current status and age at first diagnosis data. 
  • A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma. 
  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. 
  • A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. 
  • A proportional hazards model for incidence and induced remission of disease. 
  • A prospective study of weight gain after premenopausal hysterectomy. 
  • A trial of prophylactic cefamandole in extended gynecologic surgery. 
  • ACR Appropriateness Criteria® Radiologic Management of Uterine Leiomyomas. 
  • Absence of Y chromosome in human placental site trophoblastic tumor. 
  • Acoustic shadowing from uterine leiomyomas: sonographic-pathologic correlation. 
  • Addressing heterogenous outcomes in uterine fibroid research: a call to action. 
  • Advances in uterine leiomyoma research: conference overview, summary, and future research recommendations. 
  • Allelic loss at the tuberous sclerosis 2 locus in spontaneous tumors in the Eker rat. 
  • Allelotype analysis of uterine leiomyoma: localization of a potential tumor suppressor gene to a 4-cM region of chromosome 7q. 
  • Alternating weekly chemotherapy with etoposide-methotrexate-dactinomycin/cyclophosphamide-vincristine for high-risk gestational trophoblastic disease. 
  • An abnormal cervicovaginal cytology smear in uterine carcinosarcoma is an adverse prognostic sign: analysis of 25 cases. 
  • An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). 
  • Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. 
  • Analysis of sequential treatment protocols for endometriosis-associated infertility. 
  • Association Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas. 
  • Association of physical activity with development of uterine leiomyoma. 
  • Authors' response to letter to the editor: the role of core outcomes in shared decision-making for uterine fibroid treatment. 
  • Bayesian modeling of incidence and progression of disease from cross-sectional data. 
  • Bayesian modeling of multiple lesion onset and growth from interval-censored data. 
  • Bayesian models for multivariate current status data with informative censoring. 
  • Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. 
  • Benign hysterectomy performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality? 
  • Benign metastasizing leiomyoma: a rare cause of multiple pulmonary nodules. 
  • Benign prostatic hypertrophy and uterine leiomyomas: analogous or dissimilar diseases? 
  • Beyond mere obesity: effect of increasing obesity classifications on hysterectomy outcomes for uterine cancer/hyperplasia. 
  • Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer. 
  • Black Women Are More Likely Than White Women to Schedule a Uterine-Sparing Treatment for Leiomyomas. 
  • CDB-4124 does not cause apoptosis in cultured fibroid cells. 
  • Cell proliferation and apoptosis in human uterine leiomyomas and myometria. 
  • Changes in insurance coverage for cancer patients receiving brachytherapy before and after enactment of the Affordable Care Act. 
  • Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. 
  • Chemo-radiation, Then on to Surgery. 
  • Cigarette smoking and the risk of female reproductive cancer. 
  • Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience. 
  • Clinicopathological and immunohistochemical features of uterine adenomyomatous polyps. 
  • Comparative effectiveness of hysterectomy versus myomectomy on one-year health-related quality of life in women with uterine fibroids. 
  • Comparative effectiveness of uterine fibroids procedures using linked medical record and claims data. 
  • Comparative genomic hybridization studies in hydatidiform moles and choriocarcinoma: amplification of 7q21-q31 and loss of 8p12-p21 in choriocarcinoma. 
  • Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometrium. 
  • Comparing focused ultrasound and uterine artery embolization for uterine fibroids-rationale and design of the Fibroid Interventions: reducing symptoms today and tomorrow (FIRSTT) trial. 
  • Comparison of characteristics of fibroids in African American and white women undergoing premenopausal hysterectomy. 
  • Cost analysis of abdominal, laparoscopic, and robotic-assisted myomectomies. 
  • Detection bias in endometrial cancer. 
  • Development of a research agenda for uterine artery embolization: proceedings from a multidisciplinary research consensus panel. 
  • Differences between black and white patients with cancer of the uterine corpus in interval from symptom recognition to initial medical consultation (United States). 
  • Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. 
  • Diffuse adenomatoid tumor of the uterus with a serosal papillary cystic component. 
  • Disparities in Fibroid Incidence, Prognosis, and Management. 
  • Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma? 
  • Effect of Direct Marketing for Uterine Artery Embolization on Rates of Leiomyomas, Incidental Findings, and Management After Pelvic MRI. 
  • Effectiveness of health maintenance reminders provided directly to patients. 
  • Effects of long-term estrogen replacement therapy. I. Metabolic effects. 
  • Effects of long-term estrogen replacement therapy. II. Neoplasia. 
  • Effects of myomas or prior myomectomy on in vitro fertilization (IVF) performance. 
  • Effects of race and clinical factors on short-term outcomes of abdominal myomectomy. 
  • Eligibility and accessibility of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of uterine leiomyomas. 
  • Embolic microspheres within ovarian arterial vasculature after uterine artery embolization. 
  • Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. 
  • Endoscopic management of leiomyomata. 
  • Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. 
  • Epidemiology of myomas. 
  • Epidemiology of uterine leiomyomas. With an etiologic hypothesis. 
  • Epidermal growth factor receptor expression in normal and malignant endometrium. 
  • Estrogen stimulation and tamoxifen inhibition of leiomyoma cell growth in vitro and in vivo. 
  • Estrogen/antiestrogen responsiveness in an in vivo/in vitro model for myometrial tumorigenesis. 
  • Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. 
  • Evaluating genetic association among ovarian, breast, and endometrial cancer: evidence for a breast/ovarian cancer relationship. 
  • Evaluation of prognostic factors and staging in gestational trophoblastic tumor. 
  • Evaluation of squamous epithelium in adenoacanthoma and adenosquamous carcinoma of the endometrium: immunoperoxidase analysis of involucrin and keratin localization. 
  • Evidence of biomechanical and collagen heterogeneity in uterine fibroids. 
  • Expression of a mitochondrial progesterone receptor (PR-M) in leiomyomata and association with increased mitochondrial membrane potential. 
  • Expression of interleukin-1 and interleukin-1 receptor antagonists in endometrial cancer. 
  • Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. 
  • Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. 
  • FIRSTT study: randomized controlled trial of uterine artery embolization vs focused ultrasound surgery. 
  • Fibroid interventions: reducing symptoms today and tomorrow: extending generalizability by using a comprehensive cohort design with a randomized controlled trial. 
  • Fibroids and Fertility: A Comparison of Myomectomy and Uterine Artery Embolization on Fertility and Reproductive Outcomes. 
  • Fibroids in pregnancy: a growing or shrinking issue? 
  • Gene expression studies in leiomyomata: new directions for research. 
  • Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis. 
  • Gestational trophoblastic disease metastatic to the central nervous system. 
  • Gestational trophoblastic disease with coexistent normal fetus: evaluation by ultrasound-guided chorionic villus sampling. 
  • Giant uterine leiomyoma mimicking pregnancy. 
  • Global expression analysis of cancer/testis genes in uterine cancers reveals a high incidence of BORIS expression. 
  • Health care resource use for uterine fibroid tumors in the United States. 
  • High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. 
  • Histopathologic distinctions in the relationship of estrogens and endometrial cancer. 
  • Hysteroscopic Endometrial Polypectomy with Manual Vacuum Aspiration Compared to Mechanical Morcellation. 
  • Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma. 
  • Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. 
  • Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. 
  • Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus. 
  • Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis. 
  • Impact of hysterectomy and bilateral oophorectomy prevalence on rates of cervical, uterine, and ovarian cancer among American Indian and Alaska Native women, 1999-2004. 
  • Impact of precontrast T10 relaxation times on dynamic contrast-enhanced MRI pharmacokinetic parameters: T10 mapping versus a fixed T10 reference value. 
  • Incidence and risk factors for surgical intervention after uterine artery embolization. 
  • Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. 
  • Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. 
  • Injectable Clostridium histolyticum collagenase as a potential treatment for uterine fibroids. 
  • Inter- and intra-rater reproducibility of quantitative dynamic contrast enhanced MRI using TWIST perfusion data in a uterine fibroid model. 
  • Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. 
  • Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma. 
  • Large, Non-Cavity Distorting Intramural Leiomyomas Decrease Leukemia Inhibitory Factor in the Secretory Phase Endometrium. 
  • Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. 
  • Lipomatous uterine masses: potential to mimic ovarian dermoids on endovaginal sonography. 
  • Localization of tenascin in uterine sarcomas and partially transformed endometrial stromal cells. 
  • Loss of stiffness in collagen-rich uterine fibroids after digestion with purified collagenase Clostridium histolyticum. 
  • Low resistance Doppler waveforms with retained products of conception: potential for diagnostic confusion with gestational trophoblastic disease. 
  • Low-dose preoperative radiation therapy for adenocarcinoma of the endometrium. A pilot study. 
  • Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. 
  • Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? 
  • Lysosomal accumulation of drugs in drug-sensitive MES-SA but not multidrug-resistant MES-SA/Dx5 uterine sarcoma cells. 
  • Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome? 
  • Malignant transformation of the human endometrium is associated with overexpression of lactoferrin messenger RNA and protein. 
  • Management of uterine fibroids. 
  • Management of uterine leiomyomata: what do we really know? 
  • Mechanical Signaling and Extracellular Matrix in Uterine Fibroids. 
  • Mechanical homeostasis is altered in uterine leiomyoma. 
  • Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. 
  • Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer. 
  • Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. 
  • Minimally invasive surgery for endometrial cancer: the horse is already out of the barn. 
  • Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. 
  • Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. 
  • Mutational analysis of the PTEN gene in human uterine sarcomas. 
  • Myometrial hyperplasia mimics the clinical presentation of uterine fibroids: a report of 3 cases. 
  • NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. 
  • Nausea and vomiting of pregnancy: role of human chorionic gonadotropin and 17-hydroxyprogesterone. 
  • Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies. 
  • Negative control elements and cAMP responsive sequences in the tissue-specific expression of mouse renin genes. 
  • On the Road to Safer Morcellation. 
  • Outcomes in surgical stage I uterine papillary serous carcinoma. 
  • Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. 
  • Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma. 
  • Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. 
  • PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. 
  • Pathologic Malgaigne fracture following pelvic irradiation. A case report. 
  • Pathology and pathophysiology of uterine smooth-muscle tumors. 
  • Pathology of gestational trophoblastic disease. 
  • Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. 
  • Pelvic mass presenting as meralgia paresthetica. 
  • Periprocedural outcomes comparing fibroid embolization and focused ultrasound: a randomized controlled trial and comprehensive cohort analysis. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Photo quiz. Vaginal bleeding at 16 weeks. 
  • Placental site trophoblastic tumor arising from antecedent molar pregnancy. 
  • Placental site trophoblastic tumor presenting as a friable cervical mass. 
  • Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. 
  • Potential nonhormonal therapeutics for medical treatment of leiomyomas. 
  • Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. 
  • Pregnancy-related fibroid reduction. 
  • Preliminary experience with robot-assisted laparoscopic myomectomy. 
  • Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. 
  • Preservation of the endometrial enhancement after magnetic resonance imaging-guided high-intensity focused ultrasound ablation of submucosal uterine fibroids. 
  • Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. 
  • Primary adenocarcinoma of the gallbladder presenting as primary gynecologic malignancy: a report of two cases. 
  • Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinoma. 
  • Prognostic factors impacting survival in early stage uterine carcinosarcoma. 
  • Prospective data collection of a new procedure by a specialty society: the FIBROID registry. 
  • Proteoglycans in Leiomyoma and Normal Myometrium: Abundance, Steroid Hormone Control, and Implications for Pathophysiology. 
  • Racial diversity in uterine leiomyoma clinical studies. 
  • Radiation Records in the National Cancer Database: Variations in Coding and/or Practice Can Significantly Alter Survival Results. 
  • Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. 
  • Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. 
  • Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. 
  • Refractory shadowing from pelvic masses on sonography: a useful diagnostic sign for uterine leiomyomas. 
  • Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions. 
  • Reproducibility of dynamic contrast-enhanced MR imaging. Part II. Comparison of intra- and interobserver variability with manual region of interest placement versus semiautomatic lesion segmentation and histogram analysis. 
  • Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers. 
  • Risk factors for postoperative urinary retention after laparoscopic and robotic hysterectomy for benign indications. 
  • Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. 
  • Risk of exogenous estrogen therapy and endometrial cancer. 
  • Risk of unanticipated abnormal gynecologic pathology at the time of hysterectomy for uterovaginal prolapse. 
  • Rodent model of reproductive tract leiomyomata. Clinical and pathological features. 
  • Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. 
  • Rodent model of reproductive tract leiomyomata: characterization and use in preclinical therapeutic studies. 
  • Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. 
  • Route of myomectomy and fertility: a prospective cohort study. 
  • Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials. 
  • Screening Magnetic Resonance Imaging-Based Prediction Model for Assessing Immediate Therapeutic Response to Magnetic Resonance Imaging-Guided High-Intensity Focused Ultrasound Ablation of Uterine Fibroids. 
  • Serum progesterone for the exclusion of early pregnancy in women at risk for recurrent gestational trophoblastic neoplasia. 
  • Short-Term Health-Related Quality of Life After Hysterectomy Compared With Myomectomy for Symptomatic Leiomyomas. 
  • Short-term quality of life after myomectomy for uterine fibroids from the COMPARE-UF Fibroid Registry. 
  • Simplified pain-control protocol after uterine artery embolization. 
  • Solitary Fibrous Tumor of the Uterus Presenting With Lung Metastases: A Case Report. 
  • Sonography of benign cystic teratoma of the ovary: pitfalls in diagnosis. 
  • Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes. 
  • Strategy for elucidating differentially expressed genes in leiomyomata identified by microarray technology. 
  • Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020. 
  • Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis. 
  • Synchronous endometrial and ovarian tumors: metastatic disease or independent primaries? 
  • Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. 
  • Systematic review highlights difficulty interpreting diverse clinical outcomes in abnormal uterine bleeding trials. 
  • The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design. 
  • The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. 
  • The Fibroid Registry for outcomes data (FIBROID) for uterine embolization: short-term outcomes. 
  • The Prevalence of Uterine Fibroids in African American Women with Hemoglobin SS Sickle Cell Disease as Determined by Pelvic Magnetic Resonance Imaging. 
  • The pathologic features and behavior of endometrial carcinoma associated with exogenous estrogen administration. 
  • The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. 
  • The promise and perils of microarray analysis. 
  • The role of optimal debulking in advanced stage serous carcinoma of the uterus. 
  • The villous stromal constituents of complete hydatidiform mole differ histologically in very early pregnancy from the normally developing placenta. 
  • Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. 
  • Total parenteral nutrition in poor prognosis gestational trophoblastic disease. 
  • Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 
  • Treatment of endometrial stromal tumors. 
  • Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate. 
  • Treatment of uterine leiomyosarcoma. 
  • Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats. 
  • Two patients with sarcoma. Case 2. Uterine sarcoma. 
  • Type 2 angiotensin II receptor is expressed in human myometrium and uterine leiomyoma and is down-regulated during pregnancy. 
  • Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative. 
  • Upper-body fat distribution and endometrial cancer risk. 
  • Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. 
  • Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. 
  • Using rheology to quantify the effects of localized collagenase treatments on uterine fibroid digestion. 
  • Uterine Cancer Mortality in White and African American Females in Southeastern North Carolina. 
  • Uterine Fibroids: Burden and Unmet Medical Need. 
  • Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. 
  • Uterine Neoplasms. Clinical Practice Guidelines in Oncology. 
  • Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. 
  • Uterine artery embolization: what more do we need to know? 
  • Uterine fibroids: Influence of "T2-Rim sign" on immediate therapeutic responses to magnetic resonance imaging-guided high-intensity focused ultrasound ablation. 
  • Uterine leiomyoma in a 14-year-old girl. 
  • Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. 
  • Vaginal Dose Is Associated With Toxicity in Image Guided Tandem Ring or Ovoid-Based Brachytherapy. 
  • Vaginal and cervical abnormalities, including clear-cell adenocarcinoma, related to prenatal exposure to stilbestrol. 
  • Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. 
  • Vitamin D and uterine leiomyomata: Is it time to let the sunshine in? 
  • Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. 
  • Why is parity protective for uterine fibroids? 
  • p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute